SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:120150383"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:120150383" > The major cat aller...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00002833naa a2200289 4500
001oai:prod.swepub.kib.ki.se:120150383
003SwePub
008240701s2010 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1201503832 URI
024a https://doi.org/10.1159/0002504352 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Gronlund, Hu Karolinska Institutet4 aut
2451 0a The major cat allergen, Fel d 1, in diagnosis and therapy
264 c 2009-10-22
264 1b S. Karger AG,c 2010
520 a Sensitization to cat is a common cause of allergic disease all over the world. Symptoms range from mild rhinoconjunctivitis to potentially life-threatening asthmatic exacerbations. In vivo and in vitro diagnostics of cat allergy is currently based on cat dander extract. As allergen extracts from natural sources are heterogeneous in composition, the allergen content may vary. With the introduction of allergens produced by recombinant techniques, a large panel of recombinant allergenic molecules including the major cat allergen, recombinant Fel d 1, has become available for immunological investigations, diagnosis and treatment. Studies have shown that this single allergen, which belongs to the uteroglobin protein family, is at least as good as cat dander extract in identifying cat-allergic patients. The introduction of recombinant Fel d 1-based tests into clinical practice will increase our knowledge of this single allergen molecule as a diagnostic tool and improve the selection for therapy of cat allergy. Several different modes for allergen-specific immunotherapy of cat allergy based on Fel d 1 have been developed. These include Fel d 1 hypoallergens and allergen constructs where Fel d 1 is coupled to immunomodulatory proteins or carriers. The approaches have been evaluated in experimental in vitro and in vivo model systems with promising results. In addition, immunotherapy with Fel d 1 peptides containing T-cell epitopes has been tested in clinical trials. After initial problems with adverse reactions, more recent data show that peptide immunotherapy modulates the immune response to Fel d 1 and reduces early- and late-phase effector reactions in cat-allergic patients.
700a Saarne, Tu Karolinska Institutet4 aut
700a Gafvelin, Gu Karolinska Institutet4 aut
700a van Hage, Mu Karolinska Institutet4 aut
710a Karolinska Institutet4 org
773t International archives of allergy and immunologyd : S. Karger AGg 151:4, s. 265-274q 151:4<265-274x 1423-0097x 1018-2438
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:120150383
8564 8u https://doi.org/10.1159/000250435

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Gronlund, H
Saarne, T
Gafvelin, G
van Hage, M
Artiklar i publikationen
International ar ...
Av lärosätet
Karolinska Institutet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy